Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: February 28, 2020

DrugPatentWatch Database Preview

Litigation Details for Miotox LLC v. Allergan, Inc. (C.D. Cal. 2014)

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Miotox LLC v. Allergan, Inc. (C.D. Cal. 2014)

Docket   Start Trial Date Filed 2014-11-10
Court District Court, C.D. California Date Terminated 2017-09-11
Cause 28:1442 Notice of Removal Assigned To Otis D. Wright II
Jury Demand Plaintiff Referred To Patrick J. Walsh
Patents 8,420,106; 8,491,917; 8,617,569; 8,722,060; 8,883,143
Attorneys Anne Y Brody; Christina R Hollander; Deborah E Fishman; Jeffrey T Martin; Jeffrey T Thomas; K Nicole Buck; K Nicole Williams; Krista Marie Carter; Mark D Petersen; Matthew C Parrott; Sean S Twomey
Firms Arnold & Porter Kaye Scholer LLP; Farella Braun and Martel LLP, Russ Building; Fish & Richardson P.C.; Gibson Dunn & Crutcher LLP; Gibson Dunn and Crutcher; Gibson Dunn and Crutcher LLP; Gibson, Dunn & Crutcher, LLP; Kaye Scholer LLP
Link to Docket External link to docket
Biologic Drugs cited in Miotox LLC v. Allergan, Inc.
The biologic drug covered by the patents cited in this case is   Start Trial .

Details for Miotox LLC v. Allergan, Inc. (C.D. Cal. 2014)

Date Filed Document No. Description Snippet Link To Document
2014-11-10 1 11 f (a) U.S. Patent No. 8,420,106, "Extramuscular Treatment of Traumatic… 23 8,420,106. A atient …Agreement § 2(a). "Licensed Patents" include "all patents and patent applications … (a) "Licensed Patents" sha]1 mean all patents and patent applications in …within the definition of Licensed Patents are any patents or patent applications which claim any Improvements External link to document
2015-10-05 228 several patent applications in 2012 including: 16 17 1. U.S. Patent No. 8,420,106, Extramuscular… 7 four patents and one patent application, which included the ’106 Patent, ’569 Patent, 8 and… All patents and patent applications in the Territory presently owned or 20 Patents …the sole patent covered by the Agreement was the ’468 2 Patent. (AUF ¶ 12.) The ’468 Patent broadly… the ’106 Patent, non-infringement of the ’143 Patent, invalidity of the 21 ’569 Patent, and unenforceability External link to document
2016-09-06 267 the patents’ 24 claims. The patent now at issue is U.S. Patent No. 8,722,060 (“the ’060 patent”), … the United States Patent and 8 Trademark Office (“USPTO”) issued U.S. Patent No. 5,714,468 to Dr…this patent. (Id. ¶¶ 12–14, Ex. 13 A.) The agreement also provided that any additional patents that… The ’060 Patent 17 In May 2012, Dr. Binder applied for the ’060 patent. (’060 Appl.,…issued the ’060 22 patent to Dr. Binder on May 13, 2014. (JA at 893.) This patent is now licensed to External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.